Freenome Inc

Freenome Inc. is a high-growth biotechnology company headquartered in South San Francisco, California. Founded in 2014, Freenome currently employs 105 individuals and has generated over $500 million in revenue. Freenome is focused on developing next-generation blood tests for the early detection of cancers. Their multiomics platform and machine learning techniques aim to identify cancer in its earliest, most treatable stages. Their initial product will focus on detecting early-stage colorectal cancer and advanced adenomas. Freenome distinguishes itself through its commitment to a mission-driven culture that emphasizes respect, collaboration, and a significant impact on both patients' lives and the company's success. The company has secured over $1.1 billion in funding from prominent investors, including Perceptive Advisors, RA Capital Management, Roche Venture Fund, Kaiser Permanente, Novartis, and the American Cancer Society’s BrightEdge Ventures. For more information about Freenome Inc., visit their website at freenome.com.